|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, we demonstrate the m<sup>6</sup>A reader YTHDF3 not only a novel target of YAP but also a key player in YAP signaling by facilitating m<sup>6</sup>A-modified lncRNA GAS5 degradation, which profile a new insight into CRC progression.
|
31619268 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, lncRNA GAS5 upregulated the expression of PTEN by functioning as a competing endogenous RNA (ceRNA) of miR-222-3p, thus inhibiting CRC cell migration and invasion and promoting cell autophagy.
|
31400607 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Initially, poor expression of GAS5 was observed in CRC tissues and cells.
|
30672001 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further qPCR assay confirmed that the CRC tissues with rs55829688 CT/TT genotypes had a higher GAS5 mRNA expression level.
|
30902880 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previous studies showed that genetic variant rs145204276 in the promoter region of GAS5 was associated with the development of human cancer including colorectal cancer and hepatocellular cancer.
|
30013899 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we conducted this study in order to analyze the association of GAS5 and miR-221 with the prognosis of CRC and preliminary study was done on proliferation, metastasis and invasion of CRC cells.
|
29630521 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Gas5 expression was lower in CRC tissues compared to the adjacent normal tissues, and is also lower in CRC cell lines than FHC cell line.
|
29308053 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
lncRNA GAS5 inhibits colorectal cancer cell proliferation via the miR‑182‑5p/FOXO3a axis.
|
30066886 |
2018 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, the expression levels of SNORD44 and GAS5 were measured in CRC tissues by quantitative RT-PCR.
|
28530127 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Cox proportional hazards model demonstrated that downregulated GAS5 expression was an independent prognostic factor for CRC (hazard ratio, 0.236; 95% confidence interval, 0.067-0.827; P=0.024).
|
28521420 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, GAS5 expression showed a statistically significant correlation with the mRNA levels of IL-10 and VEGF-A in CRC tissues.
|
28099146 |
2017 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LncRNA GAS5 is a recently identified tumor suppressor involved in several cancers, like breast cancer, prostate cancer, lung cancer, and colorectal cancer.
|
26634743 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analysis showed that the high expression levels of GAS5 or Yiya were correlated with poor prognosis of early stage CRC patients (p = 0.0206 and 0.0005 for GAS5 and Yiya, respectively).
|
27391432 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In current two-stage, case-control study, we systematically evaluated the potential role of lncRNA GAS5 and its genetic variation rs145204276 in the development and metastasis process of CRC in a Chinese population.
|
27863421 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer.
|
24926850 |
2014 |